These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8874323)

  • 1. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome.
    Lacombe L; Dalbagni G; Zhang ZF; Cordon-Cardo C; Fair WR; Herr HW; Reuter VE
    J Clin Oncol; 1996 Oct; 14(10):2646-52. PubMed ID: 8874323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG).
    Saint F; Le Frere Belda MA; Quintela R; Hoznek A; Patard JJ; Bellot J; Popov Z; Zafrani ES; Abbou CC; Chopin DK; de Medina SG
    Eur Urol; 2004 Apr; 45(4):475-82. PubMed ID: 15041112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic markers of intravesical bacillus Calmette-Guérin therapy for multiple, high-grade, stage T1 bladder cancers.
    Lee E; Park I; Lee C
    Int J Urol; 1997 Nov; 4(6):552-6. PubMed ID: 9477182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors.
    Pages F; Flam TA; Vieillefond A; Molinie V; Abeille X; Lazar V; Bressac-de Paillerets B; Mosseri V; Zerbib M; Fridman WH; Debré B; Thiounn N
    J Urol; 1998 Mar; 159(3):1079-84. PubMed ID: 9474235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between p53 over expression and response to bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer.
    Lebret T; Becette V; Barbagelatta M; Hervé JM; Gaudez F; Barré P; Lugagne PM; Botto H
    J Urol; 1998 Mar; 159(3):788-91. PubMed ID: 9474149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of p53 overexpression in bladder tumors treated with Bacillus Calmette-Guerin.
    Peyromaure M; Ravery V
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):667-70. PubMed ID: 12503212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.
    Herr HW; Schwalb DM; Zhang ZF; Sogani PC; Fair WR; Whitmore WF; Oettgen HF
    J Clin Oncol; 1995 Jun; 13(6):1404-8. PubMed ID: 7751885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superficial bladder cancer treated with bacillus Calmette-Guerin: a multivariate analysis of factors affecting tumor progression.
    Herr HW; Badalament RA; Amato DA; Laudone VP; Fair WR; Whitmore WF
    J Urol; 1989 Jan; 141(1):22-9. PubMed ID: 2908949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation.
    Ovesen H; Horn T; Steven K
    J Urol; 1997 May; 157(5):1655-9. PubMed ID: 9112499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
    Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
    Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Adjuvant Intravesical Bacillus Calmette-Guérin Treatment on Patients with High-Grade T1 Bladder Cancer.
    Novotny V; Froehner M; Ollig J; Koch R; Zastrow S; Wirth MP
    Urol Int; 2016; 96(2):136-41. PubMed ID: 26789626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.